Person: GÜNDÜZ, FEYZA
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
GÜNDÜZ
First Name
FEYZA
Name
9 results
Search Results
Now showing 1 - 9 of 9
Publication Open Access Radiological quantification of sarcopenic obesity and its role in chronic liver disease severity(2023-04-01) ÇİMŞİT, CANAN; KURŞUN, MELTEM; DEMİRCİOĞLU, ÖZLEM; GÜNDÜZ, FEYZA; DEMİRTAŞ, COŞKUN ÖZER; Çimşit C., Kurşun M., Demircioğlu Ö., Dilber F., Demirtaş C. Ö., Ergenç İ.Publication Metadata only The efficacy and tolerability of glecaprevir/pibrentasvir treatment in a real-world chronic hepatitis C patients cohort(2023-01-01) GÜNDÜZ, FEYZA; Yaras S., Demir M., Barutcu S., Yildirim A. E., GÜREL S., Ucbilek E., Kurtulmus I. A., Kayhan M. A., Vatansever S., ADANIR H., et al.Background and Aim: The aims of the present study were to evaluate the real-life efficacy and tolerability of glecaprevir (GLE)/pibrentasvir (PIB) in the treatment of patients with chronic hepatitis C (CHC). Materials and Methods: Between May 2019 and May 2022, 686 patients with CHC, treated with GLE/PIB combination from 21 participating centers in Turkiye, were enrolled in the study. Results: All patients were Caucasian, and their median age was 56 years. At the start of GLE/PIB treatment, the median serum Hepatitis C virus RNA and serum alanine amino transaminase (ALT) levels were 6.74 log10 IU/mL and 47 U/L, respectively. Fifty-three percent of the patients were infected with genotype 1b, followed by genotype 3 (17%). Diabetes was the more common concomitant disease. The sustained virological response (SVR12) was 91.4% with intent-to-treat analysis and 98.5% with per protocol analysis. The SVR12 rates were statistically significant differences between the patients who were i.v. drug users and non-user (88.0% vs. 98.8%, p=0.025). From the baseline to SVR12, the serum ALT levels and Model for End-Stage Liver Disease score were significantly improved (p<0.001 and p=0.014, respectively). No severe adverse effect was observed. Conclusion: GLE/PIB is an effective and tolerable treatment in patients with CHC.Publication Open Access Practicality and potential restrictions of unresectable hepatocellular carcinoma prognostic index(2022-09-01) DEMİRTAŞ, COŞKUN ÖZER; ÖZDOĞAN, OSMAN CAVİT; BALTACIOĞLU, FEYYAZ; ÖNEŞ, TUNÇ; YUMUK, PERRAN FULDEN; DULUNDU, ENDER; GÜNDÜZ, FEYZA; DEMİRTAŞ C. Ö. , Ricco G., ÖZDOĞAN O. C. , BALTACIOĞLU F., ÖNEŞ T., YUMUK P. F. , DULUNDU E., Uzun S., Colombatto P., Oliveri F., et al.Publication Metadata only Cleared global consortium results highlight regional variation and need for equity in inpatient outcomes in hospitalized patients with chronic liver disease(2022-07-01) GÜNDÜZ, FEYZA; Bajaj J. S., Kamath P. S., Wong F., Hayes P., İDİLMAN R., Torre A., Topazian M., George J., Reis Alvares-da-Silva M., Xie Q., et al.Publication Metadata only Eri̇şki̇nli̇kte tanı alan gli̇kojen depo ti̇p-3 olgu sunumu(2022-10-20) DİNÇER YAZAN, CEYDA; TOKAY TARHAN, SENA; GÜNDÜZ, FEYZA; YAVUZ, DİLEK; Yaşar F. Z. , Dinçer Yazan C., Tokay Tarhan S., Dilber F., Yavuz D.Publication Metadata only Differences in mortality rates in inpatients with cirrhosis depends on the low, middle or high income country location: multi-national cleared consortium experience(2022-10-01) GÜNDÜZ, FEYZA; Bajaj J. S., Wong F., Xie Q., Topazian M., Aldo T., İDİLMAN R., Alvares-Da-Silva M. R., Hayes P. C., George T., Kouacou M. J. D. L. E., et al.Publication Metadata only Low serum albumin at admission is associated with mortality among inpatients with cirrhosis: a multi-national experience(2022-10-01) GÜNDÜZ, FEYZA; Wong F., Choudhury A. K., Xie Q., İDİLMAN R., George J., Kouacou M. J. D. L. E., Allah B. H., Lah P. C. R., Debzi N., Desalegn H., et al.Publication Metadata only Preliminary results of the effectiveness and safety of tenofovir alefenamide fumarate prophylaxis in HBV-infected individuals, who received chemo/immunosuppressive therapy(2022-07-01) GÜNDÜZ, FEYZA; DEMİRTAŞ, COŞKUN ÖZER; GÜNDÜZ F., DURAK S., ÜNSAL Y., DEMİR M., Ellik Z. M., YILDIRIM A. E., Mehdiyev S., ADANIR H., DEMİRTAŞ C. Ö., ÜÇBİLEK E., et al.Publication Open Access Characteristics of patients with hepatocellular carcinoma: A multicenter study(2022-09-01) DEMİRTAŞ, COŞKUN ÖZER; KEKLİKKIRAN, ÇAĞLAYAN; GÜNDÜZ, FEYZA; ÖZDOĞAN, OSMAN CAVİT; Guzelbulut F., KARAOĞULLARINDAN Ü., AKKIZ H., ALTINTAŞ E., DEMİRTAŞ C. Ö. , Bahadir O., KEKLİKKIRAN Ç., YILDIRIM A. E. , Gumussoy M., Balci H. R. , et al.Background and Aim: The aim of the present study was to examine the etiology of hepatocellular carcinoma (HCC) by underlying cause and determine the characteristics and clinical features of patients with HCC. Materials and Methods: The study comprised 1802 HCC patients diagnosed and followed up by Liver Diseases Outpatient Clinics in 14 tertiary centers in Turkey between 2001 and 2020. Results: The mean age was 62.3±10.7 years, and 78% of them were males. Of the patients, 82% had cirrhosis. Hepatitis B virus (HBV) infection was the most common etiology (54%), followed by hepatitis C virus (HCV) infection (19%) and nonalcoholic fatty liver disease (NAFLD) (10%). Of the patients, 56% had a single lesion. Macrovascular invasion and extrahepatic spread were present in 15% and 12% of the patients, respectively. The median serum alpha-fetoprotein level was 25.4 ng/mL. In total, 39% of the patients fulfilled the Milan Criteria. When we compared the characteristics of patients diagnosed before and after January 2016, the proportion of NAFLD-related HCC cases increased after 2016, from 6.6% to 13.4%. Conclusion: Chronic HBV and HCV infections remain the main causes of HCC in Turkey. The importance of NAFLD as a cause of HCC is increasing